Nov 6 (Reuters) - Auxilium Pharmaceuticals Inc reported a better-than-expected adjusted quarterly profit due to high sales of its urology drugs and raised the lower end of its full-year revenue forecast.
The company said it now expected full-year revenue of $370 million to $401 million. It had earlier estimated $363 million to $405 million.
Auxilium's net loss widened to $28.9 million, or 59 cents per share, in the third quarter ended Sept. 30 from $10.5 million, or 21 cents per share, a year earlier.
Excluding items, the company earned 17 cents per share.
Analysts on average had expected 15 cents, according to Thomson Reuters I/B/E/S.